Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway

References

• Ferlay JE, Lam F, Colombet M, et al. Global cancer observatory: cancer today international agency for research on cancer. Lyon, France: International Agency for Research on Cancer; 2020. [cited 2021 Jul 07]. Available from: https://gco.iarc.fr/today/home.
   Google Scholar
• Lavi A, Cohen M. [PROSTATE cancer early detection using psa – current trends AND recent updates]. Harefuah. 2017;156(3):185–188.
   PubMedGoogle Scholar
• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–An update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Cancer Registry of Norway. Cancer in Norway 2020 – Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2021.
   Google Scholar
• Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200.
   PubMed Web of Science ®Google Scholar
• Pernar CH, Ebot EM, Wilson KM, et al. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361–18.
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–383.
   PubMedGoogle Scholar
• Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232–237.
   PubMed Web of Science ®Google Scholar
• Komura K, Sweeney CJ, Inamoto T, et al. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231.
   PubMed Web of Science ®Google Scholar
• Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer. 2015;137(12):2795–2802.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Liu Y, Platz EA, et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–1578.
   PubMed Web of Science ®Google Scholar
• Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem. 2004;91(3):553–571.
   PubMed Web of Science ®Google Scholar
• Hurwitz LM, Agalliu I, Albanes D, et al. Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. J Natl Cancer Inst. 2021;113(6):727–734.
   PubMedGoogle Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Garcia-Marques F, Liu S, Totten SM, et al. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022;82(5):605–616.
   PubMed Web of Science ®Google Scholar
• Langseth H, Gislefoss RE, Martinsen JI, et al. Cohort profile: the janus serum bank cohort in Norway. Int J Epidemiol. 2017;46(2):403–404g. g
   PubMed Web of Science ®Google Scholar
• Hjerkind KV, Gislefoss RE, Tretli S, et al. Cohort profile update: the janus serum bank cohort in Norway. Int J Epidemiol. 2017;46(4):1101–1102f. f
   PubMed Web of Science ®Google Scholar
• Norwegian Prostate Cancer Registry. Årsrapport for prostatakreft 2021. [Annual Report 2021]. Norwegian Oslo: Cancer Registry of Norway; 2022.
   Google Scholar
• Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231.
   PubMed Web of Science ®Google Scholar
• Fagerland MW, Lydersen S, Laake P. The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC Med Res Methodol. 2013;13:91.
   PubMed Web of Science ®Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.
   PubMed Web of Science ®Google Scholar
• Lydersen S, Fagerland MW, Laake P. Categorical data and contingency tables. In Veierod MB, Lydersen S, Laake P, editors. Medical statistics in clinical and epidemiological research. 1th ed. Oslo, Norway: Gyldendal Akademisk; 2012. p. 48–89.
   Google Scholar
• Breidablik HJ, Meland E, Aakre KM, et al. PSA measurement and prostate cancer – overdiagnosis and overtreatment? Tidsskr Nor Laegeforen. 2013;133(16):1711–1716.
   PubMedGoogle Scholar
• Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. Lancet. 2021;398(10305):1075–1090.
   PubMed Web of Science ®Google Scholar
• Desai MM, Cacciamani GE, Gill K, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3):e222246.
   PubMed Web of Science ®Google Scholar
• Cook RJ. Kappa and its dependence on marginal rates. Encyclopedia of Biostatistics. Wiley StatsRef; 2005.
   Google Scholar
• Hernes E, Johansson LA, Fosså SD, et al. High prostate cancer mortality in Norway evaluated by automated classification of medical entities. Eur J Cancer Prev. 2008;17(4):331–335.
   PubMed Web of Science ®Google Scholar
• Löffeler S, Halland A, Weedon-Fekjær H, et al. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52(2):122–128.
   PubMed Web of Science ®Google Scholar
• Statistics Norway. Statistikkbanken: Immigrants and Norwegian-born to immigrant parents statistics Norway. Oslo, Norway: Statistics Norway; 2022 [cited Apr 14].
   Google Scholar